1. Home
  2. EPRX vs ASRT Comparison

EPRX vs ASRT Comparison

Compare EPRX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPRX
  • ASRT
  • Stock Information
  • Founded
  • EPRX 2011
  • ASRT 1995
  • Country
  • EPRX Canada
  • ASRT United States
  • Employees
  • EPRX N/A
  • ASRT N/A
  • Industry
  • EPRX
  • ASRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EPRX
  • ASRT Health Care
  • Exchange
  • EPRX NYSE
  • ASRT Nasdaq
  • Market Cap
  • EPRX 111.1M
  • ASRT 91.3M
  • IPO Year
  • EPRX N/A
  • ASRT 1997
  • Fundamental
  • Price
  • EPRX $3.33
  • ASRT $0.92
  • Analyst Decision
  • EPRX Strong Buy
  • ASRT Strong Buy
  • Analyst Count
  • EPRX 1
  • ASRT 4
  • Target Price
  • EPRX $9.00
  • ASRT $3.19
  • AVG Volume (30 Days)
  • EPRX 24.6K
  • ASRT 908.1K
  • Earning Date
  • EPRX 02-07-2025
  • ASRT 11-11-2024
  • Dividend Yield
  • EPRX N/A
  • ASRT N/A
  • EPS Growth
  • EPRX N/A
  • ASRT N/A
  • EPS
  • EPRX N/A
  • ASRT N/A
  • Revenue
  • EPRX N/A
  • ASRT $125,763,000.00
  • Revenue This Year
  • EPRX N/A
  • ASRT N/A
  • Revenue Next Year
  • EPRX N/A
  • ASRT $1.84
  • P/E Ratio
  • EPRX N/A
  • ASRT N/A
  • Revenue Growth
  • EPRX N/A
  • ASRT N/A
  • 52 Week Low
  • EPRX $2.20
  • ASRT $0.73
  • 52 Week High
  • EPRX $4.08
  • ASRT $1.80
  • Technical
  • Relative Strength Index (RSI)
  • EPRX N/A
  • ASRT 43.20
  • Support Level
  • EPRX N/A
  • ASRT $0.90
  • Resistance Level
  • EPRX N/A
  • ASRT $1.04
  • Average True Range (ATR)
  • EPRX 0.00
  • ASRT 0.06
  • MACD
  • EPRX 0.00
  • ASRT -0.00
  • Stochastic Oscillator
  • EPRX 0.00
  • ASRT 14.84

About EPRX EUPRAXIA PHARMACEUTICALS INC

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: